|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5 Pt 1
|
|
pubmed:dateCreated |
2000-5-23
|
|
pubmed:abstractText |
Monobenzylether of hydroquinone is used worldwide to remove residual pigment in patients with vitiligo universalis. Because of the side effects reported with this drug, the use of monobenzylether of hydroquinone has been restricted in The Netherlands.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0190-9622
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
760-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10775851-Administration, Topical,
pubmed-meshheading:10775851-Adolescent,
pubmed-meshheading:10775851-Adult,
pubmed-meshheading:10775851-Aged,
pubmed-meshheading:10775851-Anisoles,
pubmed-meshheading:10775851-Combined Modality Therapy,
pubmed-meshheading:10775851-Female,
pubmed-meshheading:10775851-Humans,
pubmed-meshheading:10775851-Laser Therapy,
pubmed-meshheading:10775851-Lasers,
pubmed-meshheading:10775851-Male,
pubmed-meshheading:10775851-Middle Aged,
pubmed-meshheading:10775851-Recurrence,
pubmed-meshheading:10775851-Retrospective Studies,
pubmed-meshheading:10775851-Skin Pigmentation,
pubmed-meshheading:10775851-Vitiligo
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser.
|
|
pubmed:affiliation |
Netherlands Institute for Pigmentary Disorders, Amsterdam.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
